CA2769406A1 - Biomarqueurs du cancer du poumon - Google Patents
Biomarqueurs du cancer du poumon Download PDFInfo
- Publication number
- CA2769406A1 CA2769406A1 CA2769406A CA2769406A CA2769406A1 CA 2769406 A1 CA2769406 A1 CA 2769406A1 CA 2769406 A CA2769406 A CA 2769406A CA 2769406 A CA2769406 A CA 2769406A CA 2769406 A1 CA2769406 A1 CA 2769406A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- binds
- protein
- seq
- lung cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 87
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 85
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 85
- 239000000107 tumor biomarker Substances 0.000 title description 10
- 238000000034 method Methods 0.000 claims abstract description 60
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 93
- 108090000623 proteins and genes Proteins 0.000 claims description 89
- 102000004169 proteins and genes Human genes 0.000 claims description 87
- 108091007433 antigens Proteins 0.000 claims description 74
- 102000036639 antigens Human genes 0.000 claims description 74
- 239000000427 antigen Substances 0.000 claims description 72
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 45
- 230000027455 binding Effects 0.000 claims description 44
- 210000004027 cell Anatomy 0.000 claims description 38
- 239000012634 fragment Substances 0.000 claims description 35
- 210000004408 hybridoma Anatomy 0.000 claims description 33
- 102000014702 Haptoglobin Human genes 0.000 claims description 25
- 108050005077 Haptoglobin Proteins 0.000 claims description 25
- 239000003153 chemical reaction reagent Substances 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 101710122541 Haptoglobin-related protein Proteins 0.000 claims description 14
- 102100027772 Haptoglobin-related protein Human genes 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 102100035987 Leucine-rich alpha-2-glycoprotein Human genes 0.000 claims description 9
- 238000002493 microarray Methods 0.000 claims description 9
- 101710083711 Leucine-rich alpha-2-glycoprotein Proteins 0.000 claims description 8
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 claims description 6
- 101000737574 Homo sapiens Complement factor H Proteins 0.000 claims description 6
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 claims description 5
- 101000783723 Homo sapiens Leucine-rich alpha-2-glycoprotein Proteins 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 102000045512 human CFH Human genes 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 239000011325 microbead Substances 0.000 claims description 4
- 101100167771 Homo sapiens C9 gene Proteins 0.000 claims description 3
- 102000050086 human LRG1 Human genes 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 claims description 2
- 230000008105 immune reaction Effects 0.000 claims description 2
- 102100035432 Complement factor H Human genes 0.000 claims 2
- 101001078385 Homo sapiens Haptoglobin Proteins 0.000 claims 1
- 102000050796 human HP Human genes 0.000 claims 1
- 238000012744 immunostaining Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 32
- 201000011510 cancer Diseases 0.000 abstract description 31
- 239000000203 mixture Substances 0.000 abstract description 9
- 238000003384 imaging method Methods 0.000 abstract description 8
- 238000012544 monitoring process Methods 0.000 abstract description 7
- 238000011282 treatment Methods 0.000 abstract description 4
- 238000009509 drug development Methods 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 description 89
- 239000000523 sample Substances 0.000 description 29
- 238000002474 experimental method Methods 0.000 description 25
- 238000012216 screening Methods 0.000 description 25
- 239000000090 biomarker Substances 0.000 description 23
- 238000002965 ELISA Methods 0.000 description 19
- 102000016550 Complement Factor H Human genes 0.000 description 18
- 108010053085 Complement Factor H Proteins 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 238000005516 engineering process Methods 0.000 description 18
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 18
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 239000006228 supernatant Substances 0.000 description 14
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 11
- 238000004949 mass spectrometry Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000010606 normalization Methods 0.000 description 10
- 238000002823 phage display Methods 0.000 description 10
- 230000035945 sensitivity Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 102000003886 Glycoproteins Human genes 0.000 description 9
- 108090000288 Glycoproteins Proteins 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 108090001008 Avidin Proteins 0.000 description 8
- 102000004506 Blood Proteins Human genes 0.000 description 8
- 108010017384 Blood Proteins Proteins 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 108010026552 Proteome Proteins 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 208000009956 adenocarcinoma Diseases 0.000 description 7
- 239000011324 bead Substances 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 7
- 235000020958 biotin Nutrition 0.000 description 7
- 239000011616 biotin Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 7
- 238000007619 statistical method Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000019693 Lung disease Diseases 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 102000035122 glycosylated proteins Human genes 0.000 description 5
- 108091005608 glycosylated proteins Proteins 0.000 description 5
- 208000003849 large cell carcinoma Diseases 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 229920000126 latex Polymers 0.000 description 5
- 239000002523 lectin Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 239000000700 radioactive tracer Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 201000009030 Carcinoma Diseases 0.000 description 4
- 101001081315 Homo sapiens Haptoglobin-related protein Proteins 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 102000050284 human HPR Human genes 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000000391 smoking effect Effects 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 3
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- -1 heat shock Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004901 leucine-rich repeat Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000007837 multiplex assay Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- 108010088201 squamous cell carcinoma-related antigen Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 101150117204 C9 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010027644 Complement C9 Proteins 0.000 description 2
- 102100031037 Complement component C9 Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010076282 Factor IX Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000006167 equilibration buffer Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101710192393 Attachment protein G3P Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 101150063074 HP gene Proteins 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 102000018317 Keratin-19 Human genes 0.000 description 1
- 238000001282 Kruskal–Wallis one-way analysis of variance Methods 0.000 description 1
- 102000000853 LDL receptors Human genes 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 101100431670 Rattus norvegicus Ybx3 gene Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 208000028743 anhaptoglobinemia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 108010036226 antigen CYFRA21.1 Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000002041 carbon nanotube Substances 0.000 description 1
- 229910021393 carbon nanotube Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FRTGEIHSCHXMTI-UHFFFAOYSA-N dimethyl octanediimidate Chemical compound COC(=N)CCCCCCC(=N)OC FRTGEIHSCHXMTI-UHFFFAOYSA-N 0.000 description 1
- LRPQMNYCTSPGCX-UHFFFAOYSA-N dimethyl pimelimidate Chemical compound COC(=N)CCCCCC(=N)OC LRPQMNYCTSPGCX-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 201000008752 progressive muscular atrophy Diseases 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028646 regulation of complement activation Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23105109P | 2009-08-04 | 2009-08-04 | |
| US61/231,051 | 2009-08-04 | ||
| US28974509P | 2009-12-23 | 2009-12-23 | |
| US61/289,745 | 2009-12-23 | ||
| PCT/EP2010/061354 WO2011015602A2 (fr) | 2009-08-04 | 2010-08-04 | Biomarqueurs du cancer du poumon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2769406A1 true CA2769406A1 (fr) | 2011-02-10 |
Family
ID=42951214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2769406A Abandoned CA2769406A1 (fr) | 2009-08-04 | 2010-08-04 | Biomarqueurs du cancer du poumon |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2462164A2 (fr) |
| CA (1) | CA2769406A1 (fr) |
| WO (1) | WO2011015602A2 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10837970B2 (en) | 2017-09-01 | 2020-11-17 | Venn Biosciences Corporation | Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0915515D0 (en) | 2009-09-04 | 2009-10-07 | Ucl Business Plc | Treatment of vasculoproliferative conditions |
| ES2701075T3 (es) * | 2011-07-01 | 2019-02-20 | Univ Pennsylvania | Anticuerpos antiproperdina y usos de estos |
| EP2822573B1 (fr) * | 2012-03-09 | 2017-08-16 | UCL Business Plc. | Traitement contre le cancer |
| CN104870474B (zh) | 2012-10-04 | 2019-03-12 | 诺沃姆德治疗公司 | 用于治疗溶血性疾病的旁路途径特异性抗体 |
| CN103926413A (zh) * | 2014-04-28 | 2014-07-16 | 刘红莉 | 一种用尿液进行癌症快速检测的试剂条的制备方法 |
| GB201503438D0 (en) | 2015-02-27 | 2015-04-15 | Ucl Business Plc | Antibodies |
| KR102078310B1 (ko) * | 2015-09-11 | 2020-02-19 | 주식회사 압타머사이언스 | 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법 |
| CN107356761B (zh) * | 2016-05-09 | 2020-03-31 | 上海华盈生物医药科技有限公司 | 接骨木凝集素及结合珠蛋白相关蛋白的用途 |
| GB201702792D0 (en) * | 2017-02-21 | 2017-04-05 | Queens Univ Of Belfast | A new biomarker for preeclampsia |
| EP3798227A4 (fr) * | 2018-05-09 | 2022-03-02 | Good T Cells, Inc. | Épitope d'antigène de surface de lymphocyte t régulateur et anticorps se liant de manière spécifique à celui-ci |
| KR20210073547A (ko) * | 2018-10-09 | 2021-06-18 | 세키스이 메디칼 가부시키가이샤 | 류신 리치 α2 글리코 단백질 조성물 |
| EP3671210A1 (fr) * | 2018-12-21 | 2020-06-24 | Biosystems International KFT | Biomarqueurs épitomiques de protéines du cancer du poumon |
| US11940448B2 (en) | 2020-03-31 | 2024-03-26 | Seattle Children's Hospital | Proteomic screening for lysosomal storage diseases |
| WO2024050524A1 (fr) * | 2022-09-01 | 2024-03-07 | University Of Georgia Research Foundation, Inc. | Compositions et procédés de direction de l'apolipoprotéine l1 en vue d'induire la mort de cellules de mammifère |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| JPS5441129A (en) | 1977-09-07 | 1979-04-02 | Minolta Camera Co Ltd | Modified gauss type photographic lens |
| FR2724182B1 (fr) | 1994-09-02 | 1996-12-13 | Pasteur Institut | Obtention d'un anticorps monoclonal recombinant a partir d'un anticorps monoclonal humain anti-rhesus d, sa production en cellules d'insecte, et ses utilisations |
| US20070099251A1 (en) * | 2005-10-17 | 2007-05-03 | Institute For Systems Biology | Tissue-and serum-derived glycoproteins and methods of their use |
| US7416850B2 (en) * | 2006-01-25 | 2008-08-26 | Jemmerson Ronald R | Cytochrome c and leucine-rich alpha-2-glycoprotein-1 assays, methods and antibodies |
| KR100846354B1 (ko) * | 2007-03-21 | 2008-07-15 | (주) 프로탄바이오 | 혈청 당단백질부터 분리한 폐암 진단용 마커 |
-
2010
- 2010-08-04 EP EP10739934A patent/EP2462164A2/fr not_active Ceased
- 2010-08-04 CA CA2769406A patent/CA2769406A1/fr not_active Abandoned
- 2010-08-04 WO PCT/EP2010/061354 patent/WO2011015602A2/fr active Application Filing
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10837970B2 (en) | 2017-09-01 | 2020-11-17 | Venn Biosciences Corporation | Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring |
| US11624750B2 (en) | 2017-09-01 | 2023-04-11 | Venn Biosciences Corporation | Identification and use of glycopeptides as biomarkers for diagnosis and treatment monitoring |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2462164A2 (fr) | 2012-06-13 |
| WO2011015602A2 (fr) | 2011-02-10 |
| WO2011015602A3 (fr) | 2011-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2769406A1 (fr) | Biomarqueurs du cancer du poumon | |
| DK3054298T3 (en) | METHOD OF DETECTING TUMOR IN THE ARC | |
| Jiang et al. | Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients | |
| CA2519105A1 (fr) | Anticorps monoclonal et hybridome produisant celui-ci | |
| EP2668503B1 (fr) | Biomarqueurs combinatoires destinés aux applications cliniques mises en uvre pour la gestion des patients souffrants de cancer du poumon | |
| CN108473552B (zh) | 检测外泌体蛋白eif3a的特异性自身抗体的抗原性组合物和使用其诊断肝癌的方法 | |
| US20180224455A1 (en) | Using phage epitopes to profile the immune response | |
| KR20180041467A (ko) | 코어-푸코실화 알파-페토프로테인에 특이적으로 결합하는 항체를 이용한 면역 분석법 | |
| EP2620772A1 (fr) | Biomarqueurs du cancer gastrique et leurs procédés d'utilisation | |
| JP6276992B2 (ja) | 胸膜中皮腫患者の早期発見のための分子マーカー及びその発現解析方法 | |
| US20210318316A1 (en) | Lung cancer protein epitomic biomarkers | |
| JP6122779B2 (ja) | 抗ｗｔ１抗体の測定方法 | |
| CN108139404B (zh) | 特异性地识别、结合活性结构的REIC/Dkk-3蛋白的抗体、以及使用该抗REIC/Dkk-3抗体的癌治疗的监测 | |
| CN111303289B (zh) | 抗人Tn型糖基化MUC1抗体及其用途 | |
| CN111925425B (zh) | 甲胎蛋白特异性结合多肽及应用 | |
| EP2541249A1 (fr) | Détection d'EpCAM | |
| JP6760562B2 (ja) | 卵巣明細胞癌患者の予後を予測するための情報提供方法 | |
| JP6244644B2 (ja) | 膵臓癌の検出方法及び検出用キット | |
| WO2020218121A1 (fr) | Procédé de détection de cancer et réactif de détection | |
| US20240117070A1 (en) | Recombinant antibodies, kits comprising the same, and uses thereof | |
| GUERGOVA-KURAS et al. | LLLLLGGG GGGGGGGG LLLLL GGGGGGGG | |
| KR20220122965A (ko) | 유방암에 대한 종양 특이적 항체에 결합하는 재조합 펩티드 및 용도 | |
| CN115698718A (zh) | 胰腺癌的检测方法和检测试剂 | |
| JP2014167419A (ja) | 胸膜中皮腫患者の早期発見のための分子マーカーの組合せとその発現解析方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20150729 |
|
| FZDE | Discontinued |
Effective date: 20180806 |